CLZR Candela (MM)

Candela Corporation (NASDAQ: CLZR) announced today that two studies have reported superior results on patients who benefited from the Candela Vbeam� laser treatments for bruising resulting from cosmetic procedures. The studies concluded that the Vbeam pulsed-dye laser significantly expedited the healing process, improved outcomes, and provided greater overall patient satisfaction.

A study published in the March/April 2009 edition of the Archives of Facial Plastic Surgery, entitled: �Pulsed-Dye Laser for Treating Ecchymoses After Facial Cosmetic Procedures� by DeFatta, R. J., Krishna, S., and Williams, E. F., III concluded that �the Vbeam laser treatment resulted in a 63% mean improvement in ecchymoses scores within forty-eight (48) to seventy-two (72) hours.�

The second study, a 2009 ASLMS abstract, entitled: �A Simple Solution to a Common Problem� evaluated the effectiveness and safety of the long-pulse PDL (the Vbeam) for the treatment of ecchymoses. In this study by Elizabeth Hale, M.D., Julie Karen, M.D., Chris Hunzeker, M.D., Elliot Weiss, M.D., Leonard Bernstein, M.D., Lori Brightman, M.D., Anne Chapas, M.D., and Roy Geronemus, M.D. results showed that twenty-four hours post-treatment with the Vbeam laser, the average improvement was 62% and 13% for treated and untreated bruises, respectively.

Edwin F. Williams, M.D., Director, The Williams Center Plastic Surgery Specialists, and nationally recognized plastic surgeon pioneered this breakthrough Vbeam treatment. �Anytime you penetrate the skin there is a potential for bruising and we find that it is the bruising which occurs after many of these procedures that prevents patients from getting out into the public. It is extremely difficult to cover these unsightly marks with make-up and bruising can last for a number of weeks,� said Dr. Williams. Dr. Williams continued, �After just one treatment with the Vbeam, our patients experience dramatic clearance of the injured blood vessels. This treatment is a significant differentiator to our practice and we are excited to finally be able to offer our patients a safe and easy treatment of bruising that works!�

Roy G. Geronemus, M.D., Director, Laser & Skin Surgery Center of New York, commented, �There are millions of surgical and injectable procedures performed every year which often have bruising as a side effect that can last up to two weeks.� Dr. Geronemus continued, �This is a significant new use for the Vbeam which was already our �workhorse� laser because of its efficacy and safety profile for a wide variety of applications including skin rejuvenation, the treatment of rosacea, acne, diffuse redness, scars and more.�

For more information and to request copies of the studies, visit www.candelalaser.com or call 800-733-8550, ext. 247.

About CANDELA: Candela Corporation manufactures and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, Candela markets and services its products in 86 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 20 years ago, and currently has an installed base of over 14,000 systems worldwide. Visit Candela on the Web at http://www.candelalaser.com.

Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela Corporation�s current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. These statements include declarations regarding our or our management�s beliefs and current expectations. In some cases, you can identify forward-looking statements by terminology such as �may,� �will,� �should,� �expects,� �plans,� �anticipates,� �believes,� �estimates,� �predicts,� �potential� or �continue� or the negative of such terms or other comparable terminology. These forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. The risks and uncertainties that may affect forward-looking statements include, among others: the availability of, and our ability to successfully implement strategic and operational alternatives, the pendency of re-examinations of the �844 Patent and the �568 Patent before the PTO, our alleged infringement of the �844 Patent and the �568 Patent, the validity of the �844 Patent and the �568 Patent, our expected legal expenses, our exploration of strategic and operational alternatives, the expected recovery of our industry, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock, the cancellation or deferral of customer orders, the risk of a material adverse judgment or increased litigation-related expenses in pending litigation matters, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.

Candela (MM) (NASDAQ:CLZR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Candela (MM) (NASDAQ:CLZR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024